` EX1 (Exopharm Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

EX1
vs
S
S&P/ASX 300

Over the past 12 months, EX1 has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
EX1 vs S&P/ASX 300

Loading
EX1
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EX1 vs S&P/ASX 300

Loading
EX1
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
EX1 vs S&P/ASX 300

Loading
EX1
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Exopharm Ltd vs Peers

S&P/ASX 300
EX1
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Exopharm Ltd
Glance View

Market Cap
1.6m AUD
Industry
Biotechnology

Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm is focused on developing and commercializing exosomes as therapeutic agents. The firm has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The firm is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.

EX1 Intrinsic Value
Not Available
Back to Top